An aberrant sugar modification of BACE1 blocks its lysosomal targeting in Alzheimer's disease

An aberrant sugar modification of BACE1 blocks its lysosomal targeting in Alzheimer's disease

Abstract The β‐site amyloid precursor protein cleaving enzyme‐1 (BACE1), an essential protease for the generation of amyloid‐β (Aβ) peptide, is a major drug target for Alzheimer's disease (AD). However, there is a concern that inhibiting BACE1 could also affect several physiological functions....

Full description

Saved in:
Bibliographic Details
Main Authors: Yasuhiko Kizuka, Shinobu Kitazume, Reiko Fujinawa, Takashi Saito, Nobuhisa Iwata, Takaomi C Saido, Miyako Nakano, Yoshiki Yamaguchi, Yasuhiro Hashimoto, Matthias Staufenbiel, Hiroyuki Hatsuta, Shigeo Murayama, Hiroshi Manya, Tamao Endo, Naoyuki Taniguchi
Format: Article
Language:English
Published: Springer Nature 2015-01-01
Series:EMBO Molecular Medicine
Subjects:
Alzheimer's disease (AD)
amyloid‐β (Aβ)
BACE1
bisecting GlcNAc
GnT‐III (Mgat3)
Online Access:https://doi.org/10.15252/emmm.201404438
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.15252/emmm.201404438

Similar Items